1189725-26-5 Usage
Description
Bupropion-d9 (hydrochloride) (CRM) (Item No. 22487) is a certified reference material intended for use as an internal standard for the quantification of bupropion by GC- or LC-MS. Bupropion is categorized as an antidepressant. It is also useful in promoting smoking cessation. This product is intended for research and forensic applications.
Chemical Properties
White to Off White Cyrstalline Solid
Uses
Different sources of media describe the Uses of 1189725-26-5 differently. You can refer to the following data:
1. (Bupropion D9 Hydrochloride) The isotopically labelled Bupropion, a selective inhibitor of dopamine uptake. Bupropion is an antidepressant of the aminoketone class; aid in smoking cessation
2. The isotopically labelled Bupropion ((B689625), a selective inhibitor of dopamine uptake. Bupropion is an antidepressant of the aminoketone class; aid in smoking cessation.
3. Labelled Bupropion, intended for use as an internal standard for the quantification of Bupropion by GC- or LC-mass spectrometry.
General Description
Bupropion is an antidepressant and smoking cessation drug sold under the trade names Wellbutrin? and Zyban?. Suitable uses for this certified solution standard include as an internal standard for quantitation of bupropion levels in biological matrices such as urine or isotope dilution methods by LC/MS or GC/MS for clinical toxicology, urine drug testing, or forensic analysis applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1189725-26-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,9,7,2 and 5 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1189725-26:
(9*1)+(8*1)+(7*8)+(6*9)+(5*7)+(4*2)+(3*5)+(2*2)+(1*6)=195
195 % 10 = 5
So 1189725-26-5 is a valid CAS Registry Number.
1189725-26-5Relevant articles and documents
PHENYLPROPANONE MODULATORS OF DOPAMINE RECEPTOR
-
Page/Page column 13, (2010/04/23)
The present invention relates to new phenylpropanone modulators of dopamine receptors, serotonin receptors, and/or nicotinic acetylcholine receptors, pharmaceutical compositions thereof, and methods of use thereof.